A rare and threatening complication in a cirrhotic patient [PDF]
, 2018 info:eu-repo/semantics ...
Anapaz, V, Branco, J, Reis, J, Santos, L
core +1 more source
Terlipressin-induced hyponatremic encephalopathy in a noncirrhotic patient
Kaohsiung Journal of Medical Sciences, 2013 Terlipressin, an analogue of vasopressin, is frequently used for the management of esophageal varices bleeding and hepatorenal syndrome. Terlipressin therapy in portal hypertensive patients is frequently associated with hyponatremia, but is rarely ...
Yao-Kuang Wang +5 more
doaj +1 more source
Terlipressin or norepinephrine in septic shock: do we have the answer? [PDF]
, 2019 Comment on Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial.
Russell, James A., Williams, Mark D.
core +1 more source
Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome [PDF]
Clinical and Molecular Hepatology, 2013 Terlipressin is a vasopressin analogue that is widely used in the treatment of hepatorenal syndrome or variceal bleeding. Because it acts mainly on splanchnic vessels, terlipressin has a lower incidence of severe ischemic complications than does ...
Hae Rim Kim +13 more
doaj +1 more source
Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1 [PDF]
, 2017 Background Hepatorenal syndrome type 1 (HRS1) is a functional, rapidly progressive, potentially reversible form of acute kidney injury occurring in patients with cirrhosis.
Alessandria +34 more
core +2 more sources
Frontiers in Pharmacology, 2022 Gut-vascular barrier (GVB) serves as the last barrier to limit the migration of intestinal toxins into the blood circulation. The efficacy of terlipressin (a vasopressin V1 receptor agonist) in reducing GVB and multiple organ damage in gut-derived sepsis
Zenan Chang +10 more
doaj +1 more source
The effects of vasopressin and its analogues on the liver and its disorders in the critically ill: [PDF]
, 2010 Purpose of review: Vasopressin and terlipressin, a long-acting V1a analogue, are increasingly used in intensive care. The main clinical indications are the treatment of patients with septic shock and of patients with cirrhosis, who develop variceal ...
F. Oberti +3 more
core +2 more sources
The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome
Kidney360, 2023 Key Points Hepatorenal syndrome type 1 (HRS-1) is an often fatal, but potentially reversible, kidney failure in patients with decompensated cirrhosis. Treatment with terlipressin in patients with HRS-1 is associated with a reduction in the need for RRT ...
J. Velez +8 more
semanticscholar +1 more source
GastroHep, 2022 Background. Terlipressin is a long acting synthetic analogue of vasopressin, which is used to manage variceal bleeding and hepatorenal syndrome.
Jasmohan S. Bajaj +8 more
doaj +1 more source
Initial serum sodium concentration determines the decrease in sodium level after terlipressin administration in patients with liver cirrhosis [PDF]
, 2013 BACKGROUND: Terlipressin, as a prodrug of vasopressin, has agonistic effects on the V1 receptor and partial agonistic effects on renal vasopressin V2 receptors. However, its effects on serum sodium concentration are controversial.
Dae-Hong Jeon +7 more
core +1 more source